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Multiple endocrine neoplasias are autosomal dominant disorders characterized by the occurrence of tumors in at
least two endocrine glands. Two MEN syndromes have long been known and are well characterized: the MEN type 1
(MEN1) and type 2 (MEN2). These syndromes are caused by germline mutations in the MEN1 and RET genes,
respectively, and have a different tumor spectrum. Recently, a variant of the MEN syndromes arose spontaneously in
a rat colony and was named MENX. Affected animals consistently develop multiple endocrine tumors, with a
spectrum that shares features with both MEN1 and MEN2 human syndromes. Genetic studies identified a germline
mutation in the Cdkn1b gene, encoding the p27 cell cycle inhibitor, as the causative mutation for MENX.
Capitalizing on these findings, heterozygous germline mutations in the human homologue, CDKN1B, were
searched for and identified in patients with multiple endocrine tumors. As a consequence of this discovery, a novel
human MEN syndrome, named MEN4, was recognized, which is caused by mutations in p27. Altogether, these
studies identified Cdkn1b/CDKN1B as a novel tumor susceptibility gene for multiple endocrine tumors in both rats
and humans. Here we review the characteristics of the MENX and MEN4 syndromes and we briefly address the main
function of p27 and how they are affected by MENX/4-associated mutations.
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The MENX syndrome in the rat
The multiple endocrine neoplasia X (MENX) multi-tumor
syndrome was discovered by accident when we observed
that some rats belonging to a Sprague–Dawley colony
started to spontaneously develop multiple endocrine
tumors. Specifically, these rats presented with multifocal
anterior pituitary adenoma and bilateral adrenal pheochro-
mocytoma, as well as extra-adrenal pheochromocytoma
(paraganglioma), thyroid C-cell hyperplasia, parathyroid
hyperplasia, and pancreatic islet cells hyperplasia (Figure 1)
(1). This multi-tumor syndrome was named MENX, as it
shares phenotypic features with both MEN1 and MEN2
human tumor syndromes (1).
Malignancies in MENX-affected rats show a clear pro-
gression with time: these animals develop with complete
penetrance adrenal medullary hyperplasia at 3–4 months of
age, which progresses to pheochromocytoma by 6–8 months
of age. They also present with multifocal anterior pituitary
neoplasms at about 4 months of age, which progress to
larger adenomas by 8–12 months of age (frequency 100%).
MENX mutant rats also develop pancreatic islet cell
hyperplasia (frequency 80%) and from these hyperplastic
islets, if the animal lives long enough, insulinomas may
arise (Figure 1). Due to the development of multiple
malignancies, affected rats have an average life span of
10¡2 months, whereas their wild-type littermates live
approximately 24–30 months (2). Based on the symptoma-
tology of affected rats, high blood pressure seems to be the
leading cause of morbidity, although formal proof is still
lacking.
Additional phenotypic characteristics of the MENX-
affected rats include: macroscopically visible bilateral
juvenile cataracts (1), increased body size, and organome-
galy, particularly of spleen and thymus, in mutants versus
wild-type littermates (2).
The predisposition of MENX-affected rats to develop multi-
ple endocrine tumors is inherited as a recessive trait, indicating
that they are homozygous for the underlying genetic mutation
(1). Linkage analysis followed by a positional cloning approach
allowed us to identify the gene responsible for the MENX
syndrome: the Cdkn1b gene encoding the cell cycle inhibitor
p27. Affected rats carry a tandem duplication of eight
nucleotides (c.520-528dupTTCAGAC, RefSeq: NM_031762
from base 77 to 670) in exon 2 of Cdkn1b, which causes a
frameshift (2). At the protein level, the mutated allele encodes a
protein predicted to have a novel C-terminal sequence starting
at codon 177, referred to as p27fs177. The wild-type p27 (p27wt)
protein is 198 amino acids long, whereas the mutated protein, as
a result of the frameshift, is predicted to be 221 amino acids
long. This Cdkn1b mutation was identified in homozygosity in
all MENX-affected rats tested (n.200), whereas it was never
observed in unaffected littermates or in control wild-type rats of
commercially available inbred strains (2).
Following the identification of the causative genetic
mutation, the expression of the Cdkn1b gene in MENX rats
was explored in more detail. The analysis of various tissues of
2-month-old affected rats (before they develop malignancies)
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and wild-type age-matched littermates (controls) showed
that the level of Cdkn1b mRNA is highly similar in both
animal groups. Furthermore, correct splicing of the mutant
mRNA was demonstrated in mutant rat tissues (2). When
the expression of the encoded p27 protein was assessed
by western blotting, a faint band corresponding in size to
the predicted p27 mutant protein (p27fs177) could be
observed in only some tissues (i.e. thymus and thyroid).
Immunohistochemical staining, performed with an anti-
p27-specific antibody on a broader variety of tissues,
showed extremely low (thyroid, pituitary, thymus, para-
thyroid, and brain) or absent (adrenals, lung, kidney, liver,
and testis) p27 immunoreactivity in tissues of affected rats
before they eventually developed neoplasias, whereas the
same tissues obtained from wild-type rats showed strong
nuclear positivity for p27 (2). This suggests that the MENX
mutation does not affect the transcription or processing of
Cdkn1b mRNA, but affects the amount of the encoded
protein through post-transcriptional or post-translational
mechanisms.
The discovery of CDKN1B mutations in human
patients: the MEN4 syndrome
Approximately 30% of patients who have a MEN1–like
phenotype do not carry detectable MEN1 gene mutations
(3). Although this could be because of the presence of
mutations in noncoding or regulatory sequences of the gene
that are not commonly analyzed, it also suggests that these
patients could potentially bear mutations in additional, not
yet identified, susceptibility genes. Following the identifica-
tion of the genetic mutation causing MENX syndrome in
rats, we decided to investigate whether mutations in the
human homologue CDKN1B could explain some of the
MEN1-like cases without mutations in MEN1. We screened
for the presence of CDKN1B germline mutations several
patients fulfilling these criteria and we identified a germline
heterozygous TGG.TAG (c.227G.A; RefSeq: AY890407)
nonsense mutation at codon 76 (p.Trp76stop, W76X) in a
female proband with growth hormone (GH)-secreting
pituitary adenoma (causing acromegaly; age 30 years) and
primary hyperparathyroidism (age 46 years) (2). Analysis of
the proband’s relatives confirmed that in her family, the
p27W76X mutation segregates with the predisposition to
tumors belonging to the MEN1 tumor spectrum. Indeed,
one of the proband’s sisters, also a carrier of the germline
c.227G.A mutation, developed renal angiomyolipoma (age
55 years), a tumor type that has been previously associated
with the MEN1 syndrome.
As a consequence of this discovery, other groups
identified germline mutations in patients with features
suggestive of MEN1. First, Georgitsi et al. (4) identified a
heterozygous 19-bp duplication (c.59_77dup19) in exon 1 of
the CDKN1B gene in one out of 36 European patients with a
MEN1-like phenotype and no MEN1 gene mutations. The
mutation carrier was a woman who had developed a small-
cell neuroendocrine cervical carcinoma (aged 45 years),
adrenocorticotropic hormone (ACTH)-secreting pituitary
adenoma (Cushing’s disease) (aged 46 years), and hyper-
parathyroidism (aged 47 years). The c.59_77dup19 duplica-
tion causes a frameshift, and the variant mRNA is predicted
to encode a p27 protein 69 amino acids shorter than p27wt
and with a different amino acid sequence after codon 25
(p.Lys25fs, K25fs).
Subsequently, in a study of American patients with a
family history of endocrine tumors and showing primary
hyperparathyroidism (1˚ HPT) as a common feature, three
new germline CDKN1B changes were identified: ATG-7
(g.c); c.283C.T (Pro95Ser, P95S); and c.592G.G
(stop.Gln, stop.Q) (5). The patient who had the ATG-
7(g.c) nucleotide change presented with primary hyper-
parathyroidism (aged 61 years) and a non-functioning
bilateral adrenal mass (aged 63 years). The patient with
the missense variant at codon 95 presented with 1˚ HPT,
Zollinger-Ellison syndrome (ZES) and masses in the
duodenum and pancreas (aged 50 years). The individual
with the stop.Q mutation showed primary hyperparathyr-
oidism (aged 50 years).
By screening 27 Italian patients with a tumor phenotype
suggestive of MEN1, we identified a heterozygous germline
change (c.206C.T) which, at the protein level, translates to a
Pro.Leu amino acid substitution at codon 69 (p.Pro69Leu,
Figure 1 - Histology of rat tissues affected by the MENX
syndrome. Adrenal (A, B), pituitary (C, D) and thyroid (E, F)
glands, and pancreas (G, H) of wild-type and age-matched
MENX-affected (mutant) rats. Multifocal hyperplastic lesions in
the anterior pituitary are indicated by arrows (D). A nodule of
thyroid C cell hyperplasia is also indicated (F). Pancreatic islet
cells are indicated by arrows in panels G and H: as the pictures
were taken with the same magnifications the increase in size of
the islets in mutant rats can be readily appreciated. Hematoxylin
and eosin stain (H&E) original magnification: 20X (A–D); 25X (E,
F); 40X (G, H). (Reproduced with permission from: Molatore &
Pellegata, 2010 Copyright  2010 by Elsevier).
MENX and MEN4
Pellegata NS
CLINICS 2012;67(S1):13-18
14
P69L) (6). The mutation-positive patient developed bilateral
multiple metastases of bronchial carcinoid and pituitary
non-functioning microadenoma (aged 79 years), 1˚ HPT
caused by a parathyroid adenoma (aged 67 years), and also
a papillary thyroid carcinoma (aged 64 years). The patient’s
relatives refused to undergo genetic screening, therefore the
inheritance of this mutation could not be assessed.
Recently, two novel germline CDKN1B mutations were
found by analyzing 90 common sporadic parathyroid
adenomas with non-familial presentation (7). Specifically,
one patient carried a heterozygous germline single nucleo-
tide change c.25G.A at base 25 in CDKN1B exon 1, which
would result in a Gly9Arg (G9R) substitution in the
translated p27 protein product. This patient, a 68-year old
man, had a typical, single-gland, mildly symptomatic
presentation. Another tumor contained a heterozygous
single nucleotide substitution c.397C.A, directing a
Pro133Thr (P133T) substitution in the translated p27
protein. This alteration was also present in the germline
DNA of another patient, a 53-year-old woman presenting
with fatigue, slightly elevated serum calcium and parathyr-
oid hormone levels, and a single parathyroid adenoma (7).
The CDKN1B mutations above described and the pheno-
type of the mutation carriers are summarized in Table 1,
while the location of these changes within the p27 protein is
schematically outlined in Figure 2. It is important to point
out that the CDKN1B changes described here were not
found in 192–650 alleles (depending on the study) from
healthy control individuals with no history of endocrine
tumors, nor were they identified in .2000 CDKN1B alleles
sequenced in the world literature.
As a result of the identification of patients bearing
germline CDKN1B mutations and showing multiple endo-
crine tumors, a novel MEN syndrome was recognized and
submitted to the Online Mendelian Inheritance in Man
(OMIM) database in 2007 under the name of MEN4. Owing
to the limited number of patients with MEN4 so far
reported, the precise tumor spectrum associated with this
syndrome is still not well defined (Table 1).
Function of p27 protein
p27 belongs to the kinase inhibitory protein/cyclin-depen-
dent kinase (CDK) inhibitor interacting protein (KIP/CIP)
family of cell cycle inhibitors, and its main function is to
control the progression from G1 to S phase (8). p27 binds to,
and inhibits, cyclinE/CDK2 and cyclinA/CDK2 complexes in
response to either mitogenic or anti-mitogenic stimuli. The
targets of the CDK2 kinase are members of the retinoblastoma
(pRb) family, which upon phosphorylation, release E2F
transcription factors, thereby allowing the transcription of
genes responsible for the progression into the S phase (8).
Thus, binding of p27 to cyclinE,A/CDK2 prevents pRb
phosphorylation and stops the cells in the G1 phase
(Figure 3). p27 is also required for the cytoplasmic assembly
and nuclear import of cyclinD/CDK complexes, molecules
that promote cell cycle progression (8). Because p27 is a critical
regulator of cell cycle progression, its activity is tightly
regulated at different levels: transcriptional, translational,
and post-translational. Transcriptional regulation of the
Cdkn1b promoter (9,10) and control of mRNA translation (11)
have been described, but the best known mechanism that
regulates p27 function is post-translational, and it modulates
the abundance of the protein through ubiquitin-mediated
proteasomal degradation (12). In growth-arrested cells, p27
accumulates in the nucleus, where it binds the cyclin/CDK
complexes to block cell cycle progression (13). Upon mitogenic
stimulation, the cells need to re-enter the cell cycle, so they
rapidly eliminate p27 through proteasome-mediated degrada-
tion following two molecular pathways. The first involves the
ubiquitylation-promoting complex KPC1/KPC2 and occurs in
the cytoplasm (14), while the second pathway takes place in
the nucleus and is mediated by the ubiquitin ligase SKP2 (15).
Degradation through the KPC1 pathway occurs following
phosphorylation of p27 at the Ser10 residue and its export to
the cytoplasm (16). SKP2-mediated degradation requires the
phosphorylation of p27 at the Thr187 residue by cyclinE,A/
CDK2 complexes, an event that takes place in late G1. The
phosphorylation at Thr187 creates a recognition site for the
SKP2 ubiquitin ligase which induces p27 poly-ubiquitylation
and subsequent degradation by the proteasome (Figure 3) (15).
The complex regulation of the intracellular amount of p27
suggests that its dose is critical for tissue homeostasis. This
hypothesis is supported by the observation that mice hetero-
zygous for a null Cdkn1b allele are predisposed to tumor
formation, thereby indicating that p27 is a dose-dependent
(haplo-insufficient) tumor suppressor in mice (17).
It is important to mention that the amount of p27 is
reduced/lost in many cancers, including those of the colon,
breast, prostate, and stomach, and this down-regulation is
associated with poor prognosis (18). It was demonstrated
that in aggressive colorectal carcinoma samples, the loss/
reduction of p27 expression is caused by accelerated
proteasome-dependent degradation of the protein (19),
probably caused by increased expression of the ubiquitin
ligase SKP2 (20). This molecular mechanism to reduce the
amount of p27 has been subsequently identified in other
human tumors (18). The observation that low p27 protein
levels are often associated with no change in CDKN1B
mRNA expression in many human tumors has been
considered indirect evidence that enhanced proteolysis is
responsible for p27 down-regulation in such tumors, even
when formal evidence has not been presented.
In addition to the amount of protein, the intracellular
localization of p27 can also profoundly affect the protein’s
function. Indeed, p27wt is mainly localized in the nucleus
and in this compartment it can bind to, and inhibit, cyclin/
CDK complexes, thereby acting as a cell cycle inhibitor.
However, p27 can be mislocalized in the cytoplasm through
phosphorylation or protein binding (21), and, once confined
in this compartment, p27 may acquire additional functions
that are not completely understood. Studies on engineered
mouse strains with mutations in p27 that abolish cyclin/
CDK binding have suggested that cytoplasmic p27 may play
a pro-oncogenic role (22), possibly by interacting with Rac
and RhoA, molecules, which are involved in cell migration
(23,24). Mislocalization of p27 in the cytoplasm through
phosphorylation of Thr157 by protein kinase b (AKT) has
frequently been observed in carcinoma of the breast, and is
associated with poorer prognosis (25).
Germline mutations in p27
MENX-associated mutation. Functional in vitro studies
have been performed to understand the effect of the Cdkn1b
mutation causing MENX in rats. These analyses have
demonstrated that the p27fs177 mutant protein retains some
properties of the p27wt protein: it can localize to the nucleus
and interact with cyclin-dependent kinases (Cdk2 and Cdk4)
and, to a lesser extent, with cyclins (26). However, differently
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from p27wt, p27fs177 is highly unstable and rapidly degraded,
so that its steady-state level in vitro is always very low. The p27-
unrelated C-terminal domain of p27fs177 is responsible for the
rapid degradation of the protein, probably through protein
misfolding. Studies of primary rat newborn fibroblasts
established from wild-type unaffected and mutant rats
confirmed the rapid degradation of p27fs177, which can be
rescued by proteasome inhibition (i.e. MG132, epoxomycin, or
bortezomib treatment) and thus is mediated by the proteasome.
Specifically, degradation of p27fs177 is, at least in part,
mediated by Skp2-dependent proteasomal proteolysis (26).
Based on these findings, we postulate that reduced p27
levels, not newly acquired molecular phenotypes, trigger
tumor formation in MENX-affected rats. This establishes a
parallel with p27-deficient mice, which are also predisposed
to tumor formation (27).
MEN4-associated mutations. Most of the germline
mutations identified in patients have been studied in vitro
to understand their link to tumor predisposition. The
ATG-7(g.c) change affects the Kozac consensus sequence,
which plays a major role in the initiation of mRNA tran-
slation. The ATG-7(g.c) nucleotide substitution reduces
the translation efficiency of the variant allele, which, in
turn, causes a reduced amount of the encoded p27 protein
compared with the wild-type CDKN1B allele (5). In vitro
studies showed that the p27G9R variant is less stable than
p27wt, and that this associates with strongly reduced
expression of p27 in the tumor tissue of the mutation-
carrier individual. Moreover, p27G9R mimics a p27 protein
phosphorylated at the Ser10 residue, the major phosphory-
lation site of the protein, which regulates its localization and
stability (7). The P69L change substitutes one of the proline
residues mediating the interaction between p27wt and the
CDK2 protein. Functional studies on the p27P69L mutant
protein have demonstrated that, indeed, this protein does not
efficiently bind CDK2 (6). Moreover, p27P69L is quite
unstable in vitro, and is expressed at a reduced level both in
transfected cells and in the tissues of mutation-positive
Table 1 - Germline mutations in the CDKN1B gene, phenotype of the mutation carriers and molecular phenotype of the
p27 variant proteins. Mutations are numbered referenced to the cDNA sequence AY890407 (GenBank).
Location
number Codon Mutation
Predicted
effect
Clinical
Phenotype
of proband Molecular Phenotype Reference
Protein
expression
in vitro
Protein
localization
in vitro
Protein
Interaction
Protein
expression in
patient’s tumor
Protein
localization
in patient’s
tumor
59 UTR
-7 - ATG-7(g.c) 1˚HPT (1 PT
tumor),
bilateral
adrenal mass
NF, uterine
fibroids
Reduced N.D. N.D. N.D. N.D. Agarwal et al.,
2009
Exon 1
25 9 GGG.AGG ms, G9R 1˚HPT (1 PT
tumor)
Reduced Nuclear N.D. Reduced Nuclear Costa-Guda
et al., 2011
59-77 25 nt59_77dup19 fs, K25fs 1˚HPT, ACTH-
pituitary
adenoma,
carcinoid
tumor of the
uterine cervix
N.D. N.D. N.D. Absent - Georgitsi et al.,
2007
206 69 CCC.CTC ms, P69L 1˚HPT, NF
pituitary
adenoma,
bronchial
carcinoids,
PTC
Reduced Nuclear
cytoplasm
GRB2/Reduced Absent/reduced* Nuclear Molatore
et al., 2010
227 76 TGG.TAG ns, W76X 1˚HPT, GH-
pituitary
adenoma
Wt Cytoplasm N.D. Absent - Pellegata
et al., 2006
283 95 CCC.TCC ms, P95S 1˚HPT (2 PT
tumors), ZES,
mass in
duodenum
and tail of
pancreas
Wt N.D. GRB2/Reduced N.D. N.D. Agarwal et al.,
2009
397 133 CCC.ACA ms, P133T 1˚HPT
(1 PT tumor)
Wt Nuclear N.D. N.D. N.D. Costa-Guda
et al., 2011
Exon 2
592 198 TAG.CAG if, stop.Q 1˚HPT (3 PT
tumors)
Reduced N.D. CDK2/wt N.D. N.D. Agarwal et al.,
2009
*From this patient 2 tumor tissues were available (PT and pituitary adenoma).
UTR, untranslated region; 1˚HPT, primary hyperparathyroidism; PT, parathyoir tumor; NF, non-functioning; ms, missense; fs, frameshift; PTC, papillary
thyroid carcinoma; ns, nonsense, if, in frame; ZES, Zollinger-Ellison syndrome.
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patients. p27P69L is also less efficient than p27wt in blocking
cell growth (6). The p27W76X peptide has lost the nuclear
localization signal (Figure 2), and therefore it is mislocalized
to the cytoplasm in vitro and in vivo (in the tissues of a
mutation-positive patient) (2,6). Therefore, p27W76X can no
longer bind and inhibit cyclin–CDK complexes and, as a
consequence, this peptide has lost the ability to inhibit cell
growth when over-expressed in p27-negative GH3 pituitary
adenoma cells (6). The p27P95S variant changes one of the
residues mediating the binding of p27 to the Grb2 adaptor
protein. As a consequence of this change, the p27P95S mutant
protein does not efficiently bind to Grb2, and this may
ultimately impair the activation of the Ras signal trans-
duction pathway (5). By contrast, no molecular phenotype
could be assigned to the p27P133T variant using various in
vitro assays (7). The p27 stop.Q variant encodes a protein
Figure 2 - Schematic structure of the p27 protein and position of the germline mutations identified. The regions mediating the binding
of p27 to its major interacting partners, which are reported below the protein, are indicated. The germline mutations so far identified
in MEN4 patients are indicated above the protein sequence. NLS = nuclear localization signal.
Figure 3 - Graphic representation of the nuclear and cytoplasmic interactions of p27. Upon mitogenic stimulation, p27 is released from
cyclinE/CDK2 complexes and this dissociation from p27 activates CDK2, which, in turn, phosphorylates pRb. Phosphorylated pRb
releases the transcription factor E2F, which induces the expression of genes required for the G1 to S progression. After the dissociation
of p27 from the cyclinE/CDK2 complex in early G1 a portion of p27 is phosphorylated on Ser10 and exported into the cytoplasm
through the interaction with CRM1 (exportin). Once in the cytoplasm, p27 is ubiquitylated by the KPC1/KPC2 complex and degraded by
the proteasome. Upon mitogenic stimulation p27 becomes the substrate of the cyclinE/CDK2 complex, which phosphorylates the
protein at the Thr187 residue, thereby creating a recognition site for the SKP2 ligase, which promotes ubiquitylation-mediated
degradation of p27 by the proteasome in S phase.
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containing 60 amino acids more than p27wt. The amount of
the p27stop.Q mutant protein was lower than that of p27wt
in vitro, and it could be rescued by proteasome inhibitor
treatment. Therefore, the stop.Q variation encodes a quite
unstable p27 protein (5).
Based on how severely they affect the molecular
characteristics of p27, the various genetic changes illustrated
here have been classified as pathogenic mutations (K25fs,
P69L, W76X), potentially pathogenic mutations [ATG-
7(g.c), G9R, P95S, stop.Q] or variants of unknown
pathogenic significance (P133T). The molecular phenotype
of the various p27 mutations is summarized in Table 1.
The recognition of both the MENX (rat) and the MEN4
(human) syndromes has demonstrated that Cdkn1b/
CDKN1B is a new tumor susceptibility gene for multiple
neuroendocrine tumors in both species. The observations
summarized here, together with studies of engineered
mouse models with defective or mutant p27, confirm a
critical role for p27 in regulating cell proliferation in
neuroendocrine cells. Our hypothesis is that in these cells,
aberrant/absent p27 activity cannot be compensated for by
other cyclin–CDK inhibitors, as it occurs in tissues less
affected by lack of functional p27. This would explain the
tissue-specific susceptibility to tumor formation associated
with p27 germline mutations. As novel CDKN1B mutations
are discovered, our understanding of the relationship
between p27 and neuroendocrine tumor predisposition will
increase. The characterization of the molecular properties of
mutant p27 proteins associated with MEN4 may facilitate
the development of more effective targeted therapeutic
strategies for the patients carrying those mutations.
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